Compare ACAD & MTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | MTN |
|---|---|---|
| Founded | 1993 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.2B |
| IPO Year | 2000 | 1996 |
| Metric | ACAD | MTN |
|---|---|---|
| Price | $17.18 | $151.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 15 |
| Target Price | $30.21 | ★ $148.36 |
| AVG Volume (30 Days) | ★ 2.4M | 450.9K |
| Earning Date | 11-04-2026 | 12-09-2026 |
| Dividend Yield | N/A | ★ 5.84% |
| EPS Growth | ★ 69.12 | N/A |
| EPS | 0.51 | ★ 4.12 |
| Revenue | $726,437,000.00 | ★ $2,838,204,000.00 |
| Revenue This Year | $19.55 | $7.02 |
| Revenue Next Year | $13.34 | $3.71 |
| P/E Ratio | ★ $34.47 | $36.92 |
| Revenue Growth | ★ 40.45 | N/A |
| 52 Week Low | $15.86 | $118.51 |
| 52 Week High | $30.96 | $163.99 |
| Indicator | ACAD | MTN |
|---|---|---|
| Relative Strength Index (RSI) | 34.82 | 49.06 |
| Support Level | $15.86 | $142.17 |
| Resistance Level | $22.71 | $154.65 |
| Average True Range (ATR) | 1.20 | 4.60 |
| MACD | -0.11 | -0.84 |
| Stochastic Oscillator | 18.38 | 12.79 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.